Zevra Therapeutics (ZVRA) Enterprise Value (2015 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Enterprise Value data on file, last reported at -$200.6 million in Q1 2026.

• Quarterly Enterprise Value fell 220.31% year-over-year to -$200.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$200.6 million (down 220.31% YoY) and the FY2025 annual result came in at -$191.0 million, down 174.85% from the prior year.
• Enterprise Value slipped to -$200.6 million in Q1 2026, from -$191.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$479000.0 in Q2 2023 to a low of -$202.6 million in Q2 2025.
• A 5-year average of -$92.6 million and a median of -$68.6 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value jumped 99.38% — and 2024, when it plunged 10183.51%.
• Tracing ZVRA's Enterprise Value over 5 years: stood at -$65.9 million in 2022, then fell by 2.71% to -$67.7 million in 2023, then declined by 2.6% to -$69.5 million in 2024, then slumped by 174.85% to -$191.0 million in 2025, then fell by 5.03% to -$200.6 million in 2026.
• The last three Enterprise Value figures came in at -$200.6 million (Q1 2026), -$191.0 million (Q4 2025), and -$199.5 million (Q3 2025), per Business Quant data.